Saturday, March 1, 2014
ASH 2013 Video WIth Andrew Schorr
This was a video we did at ASH in December prior to the approval of ibrutinib. At the time, we didn't know the terminology the FDA would use to describe its "approval."
The main topic of discussion in this video is primarily how a patient goes about choosing a therapy in CLL. In many cases patients will feel comfortable with a physician recommendation, in other cases they may want to educate themselves about all their options and make their own choice.
In the midst of new treatments like ibrutinib, idelalisib, ABT-199, Gazyva etc. that can be bewildering. Not sure if this video helps sort it out or not, but it is short and hopefully worth your time